News | July 19, 2023
PrecisionLife identifies first detailed genetic risk factors for long COVID
Long COVID is a debilitating chronic condition that has affected over 100 million people globally
Long COVID is a debilitating chronic condition that has affected over 100 million people globally
With this, the number of marketing approvals for its oncology products across 75 countries has gone up to 503
The positive safety review from the DSMB enables the trial to move forward as planned, with an estimated completion date in December 2023
The company is already marketing the 4 mg and 10 mg strengths
Granules India sponsored an initiative to ignite a drug-free revolution and contribute towards an empowered society
Currently there are no vaccines approved anywhere in the world for gonorrhoea, and antimicrobial resistance to existing treatments is increasing
The booster vaccine can be administered safely to individuals who have received two doses of either Covaxin or Covishield
This trial is a multi-national, phase 2/3, open-label, randomized, controlled clinical study of utidelone injectable
The group now has 372 approvals and has so far filed over 442* ANDAs since the commencement of the filing process in FY 2003-04.
Laurus will also provide funding for the clinical trials and will launch these products in India and emerging markets
Subscribe To Our Newsletter & Stay Updated
